Phase 3 trial investigates satralizumab efficacy and safety in MOGAD, indicating promising results.
To report primary and key secondary efficacy and safety results of the Phase 3 METEOROID (NCT05271409) study investigating satralizumab in patients with MOGAD.
No takes yet. Share an insight, caveat, or question.
Levy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: